Smoldering Myeloma and MGUS: What's the Difference?

MGUS and smoldering myeloma are plasma cell conditions that sit on the path before active multiple myeloma. Neither one is active myeloma.

In MGUS, abnormal plasma cells make up less than 10 percent of the bone marrow, and there is no cancer. They release a protein called M protein, which usually turns up by chance on a blood or urine test. In most people the M protein level stays steady and causes no trouble.

Smoldering myeloma sits between MGUS and active myeloma. NCI's term for it is smoldering multiple myeloma: myeloma that does not cause any signs or symptoms. It, too, is often found when a blood or urine test is done for another condition.

Testing may include blood and urine protein studies and serum free light chains. It also often includes bone marrow testing, imaging, and blood tests for kidney function, calcium, and hemoglobin.

Ask which tests are done and which are still pending. Blood counts, bone marrow testing, chromosome studies, molecular testing, and imaging can all matter here.

Teams look at the M protein level, the free light chain result, and how much of the marrow is made of plasma cells. Imaging results and other features count too. Ask which of yours are being tracked, and what a change in each would mean.

Two people with the same label can end up with different plans. Age, symptoms, blood counts, genetic changes, and kidney function all feed into it.

MGUS is monitored, not treated. Smoldering myeloma is often monitored too, though a high-risk case may lead to a specialist discussion or a clinical trial.

Waiting can feel wrong. Here it is the plan, not a delay. Monitoring is meant to catch a change early, so treatment starts when it is actually needed. Ask your team how often you will be checked, and which test results they are watching.

• Stage and spread do not mean the same thing in blood conditions as they do in solid tumors.
• A slow-moving condition is not always harmless. It still needs follow-up.
• NCI says that in most people with MGUS the M protein level stays the same and causes no problems, but MGUS can become cancer, which is why the checks matter.
• Supportive care, infection prevention, and symptom control are part of care, not extras.

• What exact subtype do I have?
• Is it fast-growing or slow-growing?
• What genetic, chromosome, or molecular results matter?
• Do I need treatment now, or is observation reasonable?
• What symptoms or lab changes would make us act sooner?
• Is a clinical trial worth discussing?

Most people with MGUS or smoldering myeloma feel well. When they do progress, a new symptom is often the first sign. Report new symptoms. Do not wait for your next appointment.

• Call 911 or go to an emergency department if you have severe back pain along with new weakness or numbness in your legs, or trouble passing or holding urine. Pressure on the spinal cord is an emergency. Treating it early protects the ability to walk. Also go if a bone breaks after a minor bump or fall.
• Call your care team the same day if you have a temperature of 100.4°F (38°C) or higher or another sign of infection. Also call the same day if you feel very thirsty, are urinating often, and become confused, drowsy, or sick to your stomach. That combination can mean a high calcium level in the blood.
• This changes the day treatment starts. Once chemotherapy or another marrow-suppressing drug is running, a fever is a medical emergency by CDC's definition rather than a same-day call: contact the team immediately whatever the hour, and use an emergency department if nobody answers.
• Call your care team within a day or two if you have new or worsening bone pain, especially in the back or ribs, new tiredness or shortness of breath, easy bruising or bleeding, or a clear drop in how much urine you pass.

• National Cancer Institute — Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Patient Version
• MedlinePlus — Multiple Myeloma
• NCBI Bookshelf, Holland-Frei Cancer Medicine — Neurologic Oncologic Emergencies

Start with Leukemia, Lymphoma, Multiple Myeloma, Blood and Marrow Stem Cell Transplant, and CAR T-Cell Therapy.